2018 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) by Williams, Bryan et al.
  
 
 
 
 
Williams, B. et al. (2018) 2018 Practice guidelines for the management of arterial 
hypertension of the European Society of Hypertension (ESH) and the European Society 
of Cardiology (ESC). Blood Pressure, 27(6), pp. 314-340. 
 
   
There may be differences between this version and the published version. You are 
advised to consult the publisher’s version if you wish to cite from it. 
 
 
 
http://eprints.gla.ac.uk/173246/  
      
 
 
 
 
 
 
Deposited on: 8 January 2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
2018 Practice guidelines for the management of arterial 
hypertension of the European Society of Hypertension 
(ESH) and the European Society of Cardiology (ESC)  
 
ESH/ESC Task Force for the Management of Arterial Hypertension 
 
 
List of authors/Task Force members 
Bryan Williams (ESC Chairperson) (UK), Giuseppe Mancia (ESH Chairperson) (Italy), 
Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel 
Burnier (Switzerland), Denis Clement (Belgium), Antonio Coca (Spain), Giovanni De Simone (Italy), 
Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), 
Luis Ruilope (Spain), Alberto Zanchetti †, Mary Kerins (Ireland), Sverre Kjeldsen (Norway), 
Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y. H. Lip(UK), Richard Mcmanus 
(UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland),Roland Schmieder (Germany), 
Evgeny Shlyakhto (Russia), Konstantinos Tsioufis (Greece),Victor Aboyans (France), Ileana 
Desormais (France). 
 
ESH Practice Guidelines writing Task Force 
Michel Burnier, Sverre E. Kjeldsen, Guido Grassi, Krzysztof Narkiewicz, Gianfranco Parati, Reinhold 
Kreutz, Konstantinos Tsioufis, Bryan Williams, Giuseppe Mancia.      
 
†Professor Zanchetti died during the development of these Guidelines, in March 2018. He contributed 
fully to the redaction of these Guidelines, as a member of the Guidelines’ Task Force and as a section 
co-ordinator. He will be sadly missed by colleagues and friends. 
 
Short Title: 2018 Practice Guidelines for the management of hypertension 
Key words: Blood Pressure – Blood pressure measurement – Blood pressure 
treatment thresholds and targets – Hypertension-mediated organ damage – Lifestyle 
interventions – Drug therapy – Combination therapy – Device therapy – Secondary 
hypertension- Special conditions- Adherence 
Correspondence to: 
Prof. Michel Burnier 
Service of Nephrology and Hypertension 
Rue du Bugnon 17 
1011 Lausanne, Switzerland 
Email: michel.burnier@chuv.ch 
2 
 
List of abbreviations 
 
 
ABI, ankle–brachial index;  
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DHP, dihydropyridine;  
eGFR, estimated glomerular filtration rate;  
ESC, European Society of Cardiology;  
ESH, European Society of Hypertension;  
HbA1c, Haemoglobin A1c;  
HBPM, Home blood pressure monitoring;  
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RAS, renin–angiotensin system;  
RCT, randomized controlled trial;  
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SPC, single-pill combination;  
SUCH, sustained uncontrolled hypertension; 
TIA, transient ischaemic attack;  
TE, transthoracic echocardiography;  
WUCH, white coat uncontrolled hypertension 
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Summary: 
 
The key messages in 20 points 
 
1. Blood pressure, epidemiology, and risk. Globally, over 1 billion people have hypertension. As 
populations age and adopt more sedentary lifestyles, the worldwide prevalence of hypertension will 
continue to rise towards 1.5 billion by 2025. Elevated BP is the leading global contributor to premature 
death, accounting for almost 10 million deaths in 2015, 4.9 million due to ischaemic heart disease and 
3.5 million due to stroke. Hypertension is also a major risk factor for heart failure, AF, CKD, PAD, and 
cognitive decline. 
 
2. Definition of hypertension. The classification of BP and the definition of hypertension is unchanged 
from previous European guidelines, and is defined as an office SBP ≥ 140 and/or DBP ≥ 90 mmHg, 
which is equivalent to a 24-h ABPM average of ≥ 130/80 mmHg, or a HBPM  average ≥ 135/85 mmHg. 
 
3. Screening and diagnosis of hypertension. Hypertension is usually asymptomatic (hence the term 
“silent killer”). Because of its high prevalence, screening programmes should be established to ensure 
that BP is measured in all adults, at least every 5 years and more frequently in people with a high-normal 
BP. When hypertension is suspected because of an elevated screening BP, the diagnosis of hypertension 
should be confirmed either by repeated office BP measurements, over a number of visits, or by out-of-
office BP measurement using 24-h ABPM or by HBPM. 
 
4.  The importance of cardiovascular risk assessment and detection of HMOD. 
Other CV risk factors such as dyslipidaemia and metabolic syndrome frequently cluster with 
hypertension. Thus, unless the patient is already at high or very high risk due to established CVD, formal 
CV risk assessment is recommended using the SCORE system. It is important to recognise, however, 
that the presence of HMOD, especially LVH, CKD, or advanced retinopathy, further increases the risk 
of CV morbidity and mortality, and should be screened for as part of risk assessment in hypertensive 
patients because the SCORE system alone may underestimate their risk. 
 
5. Think – could this patient have secondary hypertension? For most people with hypertension, no 
underlying cause will be detected. Secondary (and potentially remediable) causes of hypertension are 
more likely to be present in people with young onset of hypertension (< 40 years), people with severe 
or treatment-resistant hypertension, or people who suddenly develop significant hypertension in midlife 
on a background of previously normal BP. Such patients should be referred for specialist evaluation. 
 
6. Treatment of hypertension – importance of lifestyle interventions. The treatment of hypertension 
involves lifestyle interventions and drug therapy. Many patients with hypertension will require drug 
therapy, but lifestyle interventions are important because they can delay the need for drug treatment or 
complement the BP-lowering effect of drug treatment. Moreover, lifestyle interventions such as sodium 
restriction, alcohol moderation, healthy eating, regular exercise, weight control and smoking cessation, 
all have health benefits beyond their impact on blood pressure. 
 
7. When to consider drug treatment of hypertension. The treatment thresholds for hypertension are 
now less conservative than they were in previous guidelines. We now recommend that patients with 
low−moderate risk grade 1 hypertension (office BP 140–159/90–99), even if they do not have HMOD, 
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should now receive drug treatment if their BP is not controlled after a period of lifestyle intervention 
alone. For higher risk patients with grade 1hypertension, including those with HMOD, or patients with 
higher grades of hypertension (e.g. grade 2 hypertension, ≥ 160/100 mmHg), we recommend initiating 
drug treatment alongside lifestyle interventions. These recommendations apply to all adults up to the 
age of 80 years. 
 
8. Special considerations in frail and older patients. It is increasingly recognised that biological rather 
than chronological age, as well as consideration of frailty and independence, are important determinants 
of the tolerability of and likely benefit from BP-lowering medications. It is important to note that even 
in the very old (i.e. > 80 years), BP-lowering therapy reduces mortality, stroke, and heart failure. Thus, 
these patients should not be denied treatment, or have treatment withdrawn simply on the basis of age. 
For people > 80 years who have not yet received treatment for their BP, treatment is recommended 
when their office SBP is ≥ 160 mmHg, provided that the treatment is well tolerated. 
 
9. How low should SBP be lowered ? This has been a hotly debated topic. A key discussion point is 
the balance of potential benefits versus potential harm or adverse effects. This is especially important 
whenever BP targets are lowered, as there is a greater potential for harm to exceed benefit. Thus, in this 
guideline, we recommend a target range. The evidence strongly suggests that lowering office SBP to < 
140 mmHg is beneficial for all patient groups, including independent older patients. There is also 
evidence to support targeting SBP to 130 mmHg for most patients, if tolerated. Even lower SBP levels 
(< 130 mmHg) will be tolerated and potentially beneficial for some patients, especially to further reduce 
the risk of stroke. SBP should not be targeted to below 120 mmHg because the balance of benefit versus 
harm becomes concerning at these levels of treated SBP. 
 
10. BP targets in old and very old patient. As discussed above, independence, frailty, and 
comorbidities will all influence treatment decisions, especially in older (≥ 65 years) and very old (> 80 
years) patients. The desired SBP target range for all patients aged > 65 years is < 140 mmHg but not < 
130 mmHg. This is lower than in previous guidelines and may not be achievable in all older patients, 
but any BP lowering towards this target is likely to be beneficial provided that the treatment is well 
tolerated. 
 
11. BP targets in patients with diabetes and/or CKD. The BP-treatment targets for patients with 
diabetes or kidney disease have been a moving target in previous guidelines because of seemingly 
contradictory results from major outcome trials and meta-analyses. For diabetes, targeting the SBP to < 
140 mmHg and towards 130 mmHg, as recommended for all other patient groups, is beneficial on major 
outcomes. Moreover, targeting SBP to < 130 mmHg, for those who will tolerate it, may further reduce 
the risk of stroke but not other major outcomes. SBP should not be lowered below 120 mmHg. For 
patients with CKD, the evidence suggests that the target BP range should be < 140 mmHg but not < 130 
mmHg. 
 
12. How low should DBP be lowered? The optimal DBP target has been less well defined, but a DBP 
target of < 80 mmHg is recommended. Some patients with stiff arteries and isolated systolic 
hypertension will already have DBP levels below this target. These are high risk patients and the low 
DBP should not discourage treatment of their elevated SBP to the recommended target, provided that 
treatment is well tolerated. 
 
13. The need to do better on BP control. A key message in this guideline is the need to do  better at 
improving BP control rates. Despite the overwhelming evidence of treatment benefit, on average, < 50% 
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of patients with treated hypertension achieve a SBP target of < 140 mmHg. Physician inertia (inadequate 
up-titration of treatment, especially from monotherapy) and poor patient adherence to treatment 
(especially when based on multiple pills) are now recognised as the major factors contributing to poor 
BP control. 
 
14. Start treatment in most patients with two drugs, not one. Monotherapy is usually inadequate 
therapy for most people with hypertension; this will be especially true now that the BP-treatment targets 
for many patients are lower than in previous guidelines. This guideline sets out to normalize the concept 
that initial therapy for the majority of patients with hypertension should be with a combination of two 
drugs, not a single drug. The only exception would be in a limited number of patients with a lower 
baseline BP close to their recommended target, who might achieve that target with a single drug, or in 
some frailer old or very old patients, in whom more gentle reduction of BP may be desirable. Evidence 
suggests that this approach will improve the speed, efficiency, and consistency of initial BP lowering 
and BP control, and is well tolerated by patients.  
 
15. A single pill strategy to treat hypertension. Poor adherence to longer-term BP lowering 
medication is now recognised as a major factor contributing to poor BP control rates. Research has 
shown a direct correlation between the number of BP-lowering pills and poor adherence to medications. 
Moreover, SPC therapy has been shown to improve adherence to treatment. SPC therapy is now the 
preferred strategy for initial two-drug combination treatment of hypertension and for three-drug 
combination therapy when required. This will control the BP in most patients with a single pill and 
could transform BP control rates. 
 
16. A simplified drug-treatment algorithm. We have simplified the treatment strategy so that patients 
with uncomplicated hypertension and many patients with a variety of comorbidities (e.g. HMOD, 
diabetes, PAD, or cerebrovascular disease) receive similar medication. We recommend a combination 
of an ACE inhibitor or ARB with a CCB or thiazide/thiazide-like diuretic as initial therapy for most 
patients. For those requiring three drugs, we recommend a combination of an ACE inhibitor or ARB 
with a CCB and a thiazide/thiazide-like diuretic. We recommend beta-blockers be used when there is a 
specific indication for their use (e.g. angina, post-myocardial infarction, HFrEF, or when heart-rate 
control is required). 
 
17. Hypertension in women and in pregnancy. In women with hypertension who are planning 
pregnancy, ACE inhibitors or ARBs and diuretics should be avoided and the preferred medications to 
lower BP, if required, include alpha-methyl dopa, labetalol, or CCBs. The same drugs are suitable if BP 
lowering is required in pregnant women. ACE inhibitors or ARBs should not be used be used in pregnant 
women. 
 
18. Is there a role for device-based therapy for the treatment of hypertension? A number of device-
based interventions have been developed and studied for the treatment of hypertension. To date, the 
results from these studies have not provided sufficient evidence to recommend their routine use. 
Consequently, the use of device-based therapies is not recommended for the treatment of hypertension, 
unless in the context of clinical studies and randomized controlled trials, until further evidence regarding 
their safety and efficacy becomes available. 
 
19. Managing cardiovascular disease risk in hypertensive patients, beyond BP− statins. For 
hypertensive patients at moderate CVD risk or higher, or those with established CVD, BP lowering 
alone will not optimally reduce their risk. These patients would also benefit from statin therapy, which 
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further reduces the risk of a myocardial infarction by approximately one-third and stroke by 
approximately one-quarter, even when BP is controlled. Similar benefits have been seen in hypertensive 
patients at the border between low and moderate risk. Thus, many more hypertensive patients would 
benefit from statin therapy than are currently receiving this treatment. 
 
20. Managing cardiovascular disease risk in hypertensive patients, beyond BP – antiplatelet 
therapy.  Antiplatelet therapy, especially low-dose aspirin, is recommended for secondary prevention 
in hypertensive patients, but is not recommended for primary prevention  (i.e. in patients without CVD). 
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1. INTRODUCTION 
 
These 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines 
for the management of arterial hypertension are designed for adults with hypertension, i.e. aged ≥18 
years. The purpose of the review and update of these guidelines was to evaluate and incorporate new 
evidence into the guideline recommendations. The specific aims of these guidelines were to produce 
pragmatic recommendations to improve the detection and treatment of hypertension, and to improve the 
poor rates of BP control by promoting simple and effective treatment strategies. 
 
1.1. Principles 
 
These fundamental principles are: (i) to base recommendations on properly conducted studies, identified 
from an extensive review of the literature; (ii) to give the highest priority to data from randomized, 
controlled trials (RCTs); (iii) to also consider well-conducted meta-analyses of RCTs as strong 
evidence. This contrasts with network meta-analyses, which we do not consider to have the same level 
of evidence because many of the comparisons are non-randomized; (iv) to recognise that RCTs cannot 
address many important questions related to the diagnosis, risk stratification, and treatment of 
hypertension, which can be addressed by observational or registry-based studies of appropriate scientific 
calibre; (v) to grade the level of scientific evidence and the strength of recommendations according to 
ESC recommendations; (vi) to recognise that opinions may differ on key recommendations, which are 
resolved by voting; and (vii) to recognise that there are circumstances in which there is inadequate or 
no evidence, but the question is important for clinical practice and cannot be ignored. In these 
circumstances, we resort to pragmatic expert opinion and endeavour to explain its rationale. 
 
1.2   What is new and what is changed in the 2018 ESC/ESH hypertension guidelines? 
 
Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present 
guidelines differ from the 2013 ones in several points indicated below (Figure 1): 
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Figure 1: Changes in ESC/ESH recommendations between 2013 and 2018 
 
 
The codes used for the classes of recommendations and level of evidence are found in 
supplementary figure 1. 
 
 
 
 
 
 
9 
 
 
10 
 
 
 
 
 
1. 3 New concepts 
 
BP measurement 
-  Wider use of out-of-office BP measurement with ABPM and/or HBPM, especially HBPM, as an 
option to confirm the diagnosis of hypertension, detect white coat and masked hypertension and 
monitor BP control. 
Less conservative treatment of BP in older and very old patients 
-  Lower BP thresholds and treatment targets for older patients – with emphasis on considerations of 
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biological rather than chronological age (i.e. the importance of frailty, independence, and the 
tolerability of treatment). 
- Recommendation that treatment should never be denied or withdrawn on the basis of age, provided 
that treatment is tolerated. 
A SPC treatment strategy to improve BP control 
-  Preferred use of two-drug combination therapy for the initial treatment of most people with 
hypertension. 
-  A single-pill treatment strategy for hypertension with the preferred use SPC therapy for most 
patients. 
-  Simplified drug-treatment algorithms with the preferred use of an ACE inhibitor or ARB combined 
with a CCB or/and a thiazide/thiazide-like diuretic as the core treatment strategy for most patients, 
with beta-blockers used for specific indications. 
New target ranges for BP in treated patients 
-  Target BP ranges for treated patients to better identify the recommended BP target and lower safety 
boundaries for treated BP, according to a patient’s age and specific comorbidities. 
 
Detecting poor adherence to drug therapy 
- A strong emphasis on the importance of evaluating treatment adherence as a major cause of poor 
BP control. 
A key role for nurses, pharmacists in the longer-term management of hypertension 
-  The important role of nurses and pharmacists in the education, support, and follow-up of 
treated hypertensive patients is emphasized as part of the overall strategy to improve BP control.  
 
2. Definitions and classifications 
 
The relationship between BP and CV and renal events is continuous, making the distinction between 
normotension and hypertension − based on cut-off BP values − somewhat arbitrary. “Hypertension” is 
defined as the level of BP at which the benefits of treatment (either with lifestyle interventions or drugs), 
unequivocally outweigh the risks of treatment, as documented by clinical trials. This evidence has been 
reviewed and provides the basis for the recommendation that the classification of BP and definition of 
hypertension remain unchanged from previous ESH/ESC guidelines (Figure 2) 
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Figure 2: Classification of office BP and definitions of hypertension grades 
 
 
a BP category is defined according to seated clinic BP and by the highest level of BP, whether systolic or diastolic.  
b Isolated systolic hypertension is graded 1, 2, or 3 according to SBP values in the ranges indicated. 
 
3. Diagnostic evaluation 
 
3.1 Evaluation of the CV risk 
 
Quantification of total CV risk (i.e. the likelihood of a person developing a CV event over a defined 
period) is an important part of the risk-stratification process for patients with hypertension. Many CV 
risk-assessment systems are available and most project 10-year risk. Since 2003, the European 
guidelines on CVD prevention have recommended use of the Systematic COronary Risk Evaluation 
(SCORE) system (Figures 3 -5) because it is based on large, representative European cohort datasets 
(available at: http://www.escardio.org/Guidelines-&-Education/Practice-tools/CVD-prevention-
toolbox/SCORE-Risk-Charts). The SCORE system only estimates the risk of fatal CV events. 
 
Figure 3: Evaluation of the CV risk: 10-year cardiovascular risk categories (SCORE) 
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Figure  4: Risk modifiers increasing CV risk estimated by the SCORE system 
 
 
 
 
 
Figure 5: Classification of hypertension stages according to BP levels, presence of risk factors,   
hypertension mediated organ damage (HMOD), or comorbidities. 
 
 
BP = blood pressure; CKD = chronic kidney disease; CV = cardiovascular; DBP = diastolic blood pressure;  
HMOD = hypertension-mediated organ damage; SBP = systolic blood pressure; SCORE = Systematic Coronary Risk 
Evaluation. CV risk is illustrated for a middle-aged male. The CV risk does not necessarily correspond to the actual risk at 
different ages. The use of the SCORE system is recommended for formal estimation of CV risk for treatment decisions. 
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3.2 Measurement of blood pressure 
 
Auscultatory or oscillometric semiautomatic or automatic sphygmomanometers are the preferred 
method for measuring BP in the doctor’s office. These devices should be validated according to 
standardized conditions and protocols. 
 
BP can be highly variable, thus the diagnosis of hypertension should not be based on a single set of BP 
readings at a single office visit, unless the BP is substantially increased (e.g. grade 3 hypertension) and 
there is clear evidence of HMOD (e.g. hypertensive retinopathy with exudates and haemorrhages, or 
LVH, or vascular or renal damage). For all others (i.e. almost all patients), repeat BP measurements at 
repeat office visits have been a long-standing strategy to confirm a persistent elevation in BP, as well 
as for the classification of the hypertension status in clinical practice and RCTs. (Figure 6) 
 
White-coat hypertension refers to the untreated condition in which BP is elevated in the office, but is 
normal when measured by ABPM, HBPM, or both. Conversely, “masked hypertension” refers to 
untreated patients in whom the BP is normal in the office, but is elevated when measured by HBPM or 
ABPM. The term “true normotension” is used when both office and out-of-office BP measurements are 
normal, and “sustained hypertension” is used when both are abnormal. In white-coat hypertension, the 
difference between the higher office and the lower out-of-office BP is referred to as the “white-coat 
effect”, and is believed to mainly reflect the pressor response to an alerting reaction elicited by office 
BP measurements by a doctor or a nurse, although other factors are probably also involved. 
 
Figure 6: Office BP measurements 
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These guidelines also support the use of out-of-office BP (i.e. HBPM and/or ABPM) (Figures 7-10) as 
an alternative strategy to repeated office BP measurements, to confirm the diagnosis of hypertension, 
when these measurements are logistically and economically feasible. This approach can provide 
important supplementary clinical information, for example, detecting white-coat hypertension, which 
should be suspected, especially in people with grade 1 hypertension on office BP measurement and in 
whom there is no evidence of HMOD or CVD. A particular challenge is the detection of masked 
hypertension. Masked hypertension is more likely in people with a BP in the high-normal range in whom 
out-of-office BP should be considered to exclude masked hypertension. Out-of-office BP measurements 
are also indicated in other specific circumstances (Figures 7-9). 
 
Figure 7: Definitions of hypertension according to office, ambulatory, and home BP levels 
 
 
Figure 8: Advantages and disadvantages of ambulatory blood pressure monitoring and home blood 
pressure monitoring  
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Figure 9: Clinical indications for HBPM or ABPM  
 
 
 
 
All adults should have their BP recorded in their medical record and be aware of their BP, and further 
screening should be undertaken at regular intervals with the frequency dependent on the BP level as 
illustrated in Figure 10. 
 
Figure 10: Screening for hypertension  
 
 
 
ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pressure monitoring.  
After detecting a specific BP category on screening, either confirm BP elevation with repeated office BP measurements 
on repeat visits, or arrange use of out-of-office BP to confirm the diagnosis of hypertension 
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3.3 Clinical evaluation 
 
The information to be obtained at the time of the first diagnosis of hypertension is indicated in the 
Figures 11-14. 
 
 
Figure 11: Key information to be collected in personal and family medical history (1)  
 
 
 
 
 
 
Figure 12: Key information to be collected in personal and family medical history (2) 
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Figure 13: Routine work-up for evaluation of hypertensive patients 
 
 
HB A1c: Glycosylated hemoglobin; eGFR: estimated glomerular filtration rate; ECG: electrocardiogram 
 
 
Figure 14: Assessments of hypertension mediated organ damage (HMOD) 
 
 
ECG: electrocardiogram; LVH: left ventricular hypertrophy; eGFR: estimated glomerular filtration rate; PWV: 
pulse wave velocity, ABI: ankle brachial index; PAD: peripheral artery disease.   
 
 
 
 
 
19 
 
4.  Treatment of hypertension 
 
The routine treatment of hypertension involves lifestyle interventions for all patients (including those 
with high normal BP) and drug therapy for most patients. 
All guidelines agree that patients with grade 2 or 3 hypertension should receive antihypertensive drug 
treatment alongside lifestyle interventions. Guidelines are also consistent in recommending that patients 
with grade 1 hypertension and high CV risk or HMOD should be treated with BP-lowering drugs. There 
has been less consistency about whether BP-lowering drugs should be offered to patients with grade 1 
hypertension and low-to-moderate CV risk or grade 1 hypertension in older patients (> 60 years), or the 
need for BP-lowering drug treatment in patients with high-normal BP levels. This uncertainty relates to 
the fact that low-risk patients with high-normal BP or grade 1 hypertension have rarely been included 
in RCTs, and that in older patients, RCTs have invariably recruited patients with at least grade 2 
hypertension.  
 
4.1 Drug treatment strategy and blood pressure targets (Figure 15-20) 
 
Figure 15. Initiation of BP-lowering treatment (lifestyle changes and medication at different initial 
office BP levels  
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Figure 16: Summary of office BP thresholds for treatment 
 
 
 
CAD: coronary artery disease; CKD: chronic kidney disease; SBP: systolic blood pressure; TIA: transient ischaemic attack. 
 
Figure 17: Office BP treatment targets in hypertensive: recommendations 
 
The level to which BP should be lowered with drug treatment will depend on the patients’ age, 
comorbidities and tolerability of treatment. Corresponding BP targets for home and ambulatory BP are 
less well established but an office BP < 130 mmHg probably corresponds to a 24hr ABPM systolic BP 
of <125 mmHg and a home average systolic BP of < 130 mmHg. 
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Figure 18: Life style changes  
 
 
 
Figure 19: Core drug-treatment strategy for uncomplicated hypertension 
 
 
 
The core algorithm is also appropriate for most patients with HMOD, cerebrovascular disease, 
diabetes, or peripheral artery disease. 
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Figure 20: Compelling and possible contraindications to the use of specific antihypertensive drugs 
 
 
 
4.2. Drug treatment strategy for specific clinical situations: coronary heart disease, chronic kidney 
disease, heart failure, atrial fibrillation (Figures 21-25) 
 
Figure 21: Drug-treatment strategy for hypertension and CAD 
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Figure 22: Drug-treatment strategy for chronic kidney disease (CKD)  
 
 
 
Figure 23: Drug-treatment strategy for hypertension and heart failure with reduced ejection 
fraction (HRrEF) 
 
Figure 24: Drug-treatment strategy for hypertension and atrial fibrillation (AF) 
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Figure 25: Treatment targets in special conditions  
 
 
CAD: coronary artery disease; CKD: chronic kidney disease; SBP: systolic blood pressure; TIA: transient ischemic attack. 
 
4.3 Device-based therapy for hypertension 
 
The actual recommendation is the following: “Use of device-based therapies is not recommended for 
the routine treatment of hypertension, unless in the context of clinical studies and RCTs, until further 
evidence regarding their safety and efficacy becomes available”. 
 
4.4. Resistant hypertension (Figures 26 and 27) 
 
Hypertension is defined as resistant to treatment when the recommended treatment strategy fails to 
lower office SBP and DBP values to below 140 mmHg and/or 90 mmHg, respectively, and the  
inadequate control of BP is confirmed by ABPM or HBPM, in patients whose adherence to therapy has 
been confirmed. The recommended treatment strategy should include appropriate lifestyle measures and 
treatment with optimal or best-tolerated doses of three or more drugs that should include a diuretic and 
typically an ACE inhibitor or ARB, and a CCB. 
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Figure 26: Resistant hypertension characteristics, secondary causes, and contributing factors 
 
 
 
Figure 27 : Resistant hypertension : recommendations 
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4.5 Secondary hypertension (Figures 28-31) 
 
Secondary hypertension is hypertension due to an identifiable cause, which may be treatable with an 
intervention specific to the cause. A high index of suspicion and earl detection of secondary 
hypertension is important because interventions may be curative, especially in younger patients. 
 
Figure 28: Patients characteristics that should raise the suspicion of secondary hypertension 
 
 
 
 
Figure 29: Commmon causes of secondary hypertension (1)  
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Figure 30: Commmon causes of secondary hypertension (2)  
 
 
 
 
Figure 31: Medications and substances that may increase blood pressure  
 
 
 
 
 
 
 
 
 
28 
 
4.6 Hypertension emergency (Figures 32-33) 
 
Hypertension emergencies are situations in which severe hypertension (grade 3) is associated with 
acute HMOD, which is often life-threatening and requires immediate but careful intervention to lower 
BP, usually with intravenous (i.v.) therapy. The rate and magnitude of increase in BP may be at least 
as important as the absolute level of BP in determining the magnitude of organ injury 
 
Figure 32: Diagnostic work-up for patients with a suspected hypertension emergency  
 
 
 
Figure 33: Hypertensive emergencies requiring immediate BP lowering with i.v. drug therapy 
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4.7 Treatment recommendations in special situations (Figure 34-42) 
 
Figure 34: White coat and masked hypertension  
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Figure 35: Hypertension in pregnancy  
 
 
 
 
 
Figure 36: Hypertension in diabetes 
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Figure 37: Hypertension in CKD  
 
 
 
 
 
 
Figure 38: Hypertension in CAD  
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Figure 39: Hypertension in LVH and heart failure 
 
 
 
 
 
 
Figure 40: Hypertension and cerebrovascular diseases 
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Figure 41: Hypertension and atrial fibrillation 
 
 
 
 
 
 
Figure 42: Hypertension in perioperative diseases 
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5. Follow-up of patients 
 
5.1 Frequency of visits 
 
After the initiation of antihypertensive drug therapy, it is important to review the patient at least once 
within the first 2 months to evaluate the effects on BP and assess possible side-effects until BP is under 
control. The frequency of review will depend on the severity of hypertension, the urgency to achieve 
BP control, and the patient’s comorbidities. 
Patients with high-normal BP or white-coat hypertension frequently have additional risk factors, 
including HMOD, and have a higher risk of developing sustained hypertension. Thus, even when 
untreated, they should be scheduled for regular follow-up (at least annual visits) to measure office and 
out-of-office BP, as well as to check the CV risk profile. 
 
5.2 Adherence to therapy  (Figure 43) 
There is growing evidence that poor adherence to treatment − in addition to physician inertia (i.e. lack 
of therapeutic action when the patient’s BP is uncontrolled) − is the most important cause of poor BP 
control. Non-adherence to antihypertensive therapy correlates with higher risk of CV events. 
 
Figure 43: Interventions that may improve drug adherence in hypertension 
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Note 
 
The levels of evidence for each of the recommendations presented in the figures can be found in the 
original publications cited below. Additional figures can also be found in the printed versions of the 
guidelines. 
The grading scale can be found as supplementary material (Supplementary figure 1). 
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Supplementary figure 1:  Class of recommendations and levels of evidence as used in the 
guidelines. 
 
 
 
